Opinion

Video

Team Approach to Meeting REMS Program Requirements

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Ke Ning, MD

Sarah Rockwell, PharmD, BCOP, explores how community oncology practices can understand and meet the requirements of risk evaluation and mitigation strategy programs, and stresses the importance of developing and implementing standard operating procedures.

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery
November 19th 2024

Outpatient Transplant and CAR T-Cell Therapy: A Paradigm Shift in Care Delivery

Alana Hippensteele, Managing Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Multiple myeloma cells | Image Credit: © Сергей Косилко - stock.adobe.com
November 11th 2024

Johnson & Johnson Seeks FDA Approval of Daratumumab for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Biliary tract cancer -- Image credit: Thipphaphone | stock.adobe.com
October 30th 2024

Emerging Therapies and Precision Medicine Offer Promising Results in Hepatocellular Carcinoma and Biliary Tract Cancer

Gabriela Aponte-Melendez, PharmD Nicole Bentivegna, PharmD, BCOP